Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Operations (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Cash from Operations data on record, last reported at 27903000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 52.71% year-over-year to 27903000.0; the TTM value through Dec 2025 reached 123343000.0, up 26.43%, while the annual FY2025 figure was 123343000.0, 26.43% up from the prior year.
  • Cash from Operations reached 27903000.0 in Q4 2025 per AMLX's latest filing, up from 30368000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 13551000.0 in Q4 2023 and bottomed at 66580000.0 in Q2 2024.
  • Average Cash from Operations over 5 years is 26687050.0, with a median of 28073500.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: surged 127.27% in 2023, then crashed 8043.97% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 28244000.0 in 2021, then tumbled by 75.96% to 49697000.0 in 2022, then skyrocketed by 127.27% to 13551000.0 in 2023, then tumbled by 535.45% to 59008000.0 in 2024, then skyrocketed by 52.71% to 27903000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 27903000.0 in Q4 2025, 30368000.0 in Q3 2025, and 25248000.0 in Q2 2025.